PuSH - Publikationsserver des Helmholtz Zentrums München: Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Morra, A.* ; Escala-Garcia, M.* ; Beesley, J.* ; Keeman, R.* ; Canisius, S.* ; Ahearn, T.U.* ; Andrulis, I.L.* ; Anton-Culver, H.* ; Arndt, V.* ; Auer, P.L.* ; Augustinsson, A.* ; Beane Freeman, L.E.* ; Becher, H.* ; Beckmann, M.W.* ; Behrens, S.* ; Bojesen, S.E.* ; Bolla, M.K.* ; Brenner, H.* ; Brüning, T.* ; Buys, S.S.* ; Caan, B.* ; Campa, D.* ; Canzian, F.* ; Castelao, J.E.* ; Chang-Claude, J.* ; Chanock, S.J.* ; Cheng, T.D.* ; Clarke, C.L.* ; Colonna, S.V.* ; Couch, F.J.* ; Cox, A.* ; Cross, S.S.* ; Czene, K.* ; Daly, M.B.* ; Dennis, J.* ; Dörk, T.* ; Dossus, L.* ; Dunning, A.M.* ; Dwek, M.* ; Eccles, D.M.* ; Ekici, A.B.* ; Eliassen, A.H.* ; Eriksson, M.* ; Evans, D.G.* ; Fasching, P.A.* ; Flyger, H.* ; Fritschi, L.* ; Gago-Dominguez, M.* ; García-Sáenz, J.A.* ; Giles, G.G.* ; Grip, M.* ; Guénel, P.* ; Gündert, M. ; Hahnen, E.* ; Haiman, C.A.* ; Håkansson, N.* ; Hall, P.* ; Hamann, U.* ; Hart, S.N.* ; Hartikainen, J.M.* ; Hartmann, A.* ; He, W.* ; Hooning, M.J.* ; Hoppe, R.* ; Hopper, J.L.* ; Howell, A.* ; Hunter, D.J.* ; Jäger, A.* ; Jakubowska, A.* ; Janni, W.* ; John, E.M.* ; Jung, A.Y.* ; Kaaks, R.* ; Keupers, M.* ; Kitahara, C.M.* ; Koutros, S.* ; Kraft, P.* ; Kristensen, V.N.* ; Kurian, A.W.* ; Lacey, J.V.* ; Lambrechts, D.* ; Le Marchand, L.* ; Lindblom, A.* ; Linet, M.* ; Luben, R.N.* ; Lubiński, J.* ; Lush, M.* ; Mannermaa, A.* ; Manoochehri, M.* ; Margolin, S.* ; Martens, J.W.M.* ; Martinez, M.E.* ; Mavroudis, D.* ; Michailidou, K.* ; Milne, R.L.* ; Mulligan, A.M.* ; Muranen, T.A.* ; Nevanlinna, H.* ; Newman, W.G.* ; Nielsen, S.F.* ; Nordestgaard, B.G.* ; Olshan, A.F.* ; Olsson, H.* ; Orr, N.* ; Park-Simon, T.W.* ; Patel, A.V.* ; Peissel, B.* ; Peterlongo, P.* ; Plaseska-Karanfilska, D.* ; Prajzendanc, K.* ; Prentice, R.L.* ; Presneau, N.* ; Rack, B.* ; Rennert, G.* ; Rennert, H.S.* ; Rhenius, V.* ; Romero, A.* ; Roylance, R.* ; Ruebner, M.* ; Saloustros, E.* ; Sawyer, E.J.* ; Schmutzler, R.K.* ; Schneeweiss, A.* ; Scott, C.* ; Shah, M.* ; Smichkoska, S.* ; Southey, M.C.* ; Stone, J.* ; Surowy, H.M.* ; Swerdlow, A.J.* ; Tamimi, R.M.* ; Tapper, W.J.* ; Teras, L.R.* ; Terry, M.B.* ; Tollenaar, R.A.E.M.* ; Tomlinson, I.* ; Troester, M.A.* ; Truong, T.* ; Vachon, C.M.* ; Wang, Q.* ; Hurson, A.N.* ; Winqvist, R.* ; Wolk, A.* ; Ziogas, A.* ; Brauch, H.* ; Garcia-Closas, M.* ; Pharoah, P.D.P.* ; Easton, D.F.* ; Chenevix-Trench, G.* ; Schmidt, M.K.*

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.

Breast Cancer Res. 23:86 (2021)

Postprint

Forschungsdaten

DOI

PMC

	Open Access Gold

Abstract
Metriken
Zusatzinfos

BACKGROUND: Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients. METHODS: We performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Analyses were based on 91,686 female patients of European ancestry from the Breast Cancer Association Consortium, including 7531 breast cancer-specific deaths over a median follow-up of 8.1 years. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP < 0.15). RESULTS: Evidence of associations with breast cancer-specific survival was observed in three patient subgroups, with variant rs5934618 in patients with grade 3 tumors (15-year-hazard ratio (HR) [95% confidence interval (CI)] 1.32 [1.20, 1.45], P = 1.4E-08, BFDP = 0.01, per G allele); variant rs4679741 in patients with ER-positive tumors treated with endocrine therapy (15-year-HR [95% CI] 1.18 [1.11, 1.26], P = 1.6E-07, BFDP = 0.09, per G allele); variants rs1106333 (15-year-HR [95% CI] 1.68 [1.39,2.03], P = 5.6E-08, BFDP = 0.12, per A allele) and rs78754389 (5-year-HR [95% CI] 1.79 [1.46,2.20], P = 1.7E-08, BFDP = 0.07, per A allele), in patients with ER-negative tumors treated with chemotherapy. CONCLUSIONS: We found evidence of four loci associated with breast cancer-specific survival within three patient subgroups. There was limited evidence for the existence of associations in other patient subgroups. However, the power for many subgroups is limited due to the low number of events. Even so, our results suggest that the impact of common germline genetic variants on breast cancer-specific survival might be limited.

Impact Factor

Scopus SNIP

Altmetric

6.466

1.466